ClinicalTrials.gg
CompletedNCT02198547MgUpdated Aug 26, 2024

Magnesium as Adjuvant for Sciatic Block

An interventional study of Magnesium Sulfate and Ropivacaine in Hallux Valgus, sponsored by Campus Bio-Medico University. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-26.

Sponsored by Campus Bio-Medico University · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of the study is to evaluate if Magnesium added to ropivacaine can reduce onset time and can enhance offset time.

Read the detailed description

Patients are randomly divided into two groups: group "M" (Ropivacaina 7,5 mg/ml with Mg 4 mg/Kg)and group"C" (without Mg).

Standard monitoring is applied to each patient in perioperative period. An indipendent observer collect data: time to perform block, sensitivity onset,motor onset, pain during surgery and complication.

In the post-operative period till 24 hours for each patient is evaluated off-set time, pain and analgesic consumption.

02

Conditions studied

  • Hallux Valgus

Browse trials for

Keywords

  • Local anesthetic adjuvant,
  • Magnesium solfatus,
  • Sciatic block
03

In context

Hallux Valgus

149 studies on the registry are indexed under Hallux Valgus; 31 are open to participants now.

This study's enrollment of 60 is close to the median of 60 across 111 interventional studies indexed under Hallux Valgus.

Browse Hallux Valgus studies →

Lead sponsor

Campus Bio-Medico University is the lead sponsor of 84 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • given consent
  • allux valgus correction surgery

Exclusion criteria

Exclusion Criteria:

  • allergy to local anesthetic
  • infection in the site of puncture
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Ropivacaine Magnesium sulfate

    Locoregional anesthesia for valgus allux correction with ropivacaine 7,5 mg/ml and Mg 4 mg/Kg. Sciatic block at popliteal level.

    Drug: Magnesium Sulfate

  • Active comparator
    Ropivacaine

    Patients undergoing allux valgus correction with locoregional anesthesia with ropivacaine 7,5 mg/ml, without MG

    Drug: Ropivacaine

Interventions

06

What researchers measure

Primary outcomes

  1. Evaluation of Mg as adjuvant to local anesthetic

    We evaluate if Mg affects onset and offset time of ropivacaine 7,5 mg/ml in sciatic block at popliteal level

    Time frame: Till 24 hours

Secondary outcomes

  1. Post-operative pain

    We evaluate post-operative pain at rest and in movement at 3-6-12-24 hours with NRS scale

    Time frame: 3 hours

  2. Post-operative analgesic consumption

    We evaluate consumption of opioid and non-opioid analgesic used in the post-operative period.

    Time frame: till 24 hours

  3. Post-operative pain

    Evaluation of pain with NRS scale

    Time frame: 6 hours

  4. post-operative pain

    Evaluation of pain with NRS scale

    Time frame: 12 hours

  5. Post-operative pain

    Evaluation of pain with NRS scale

    Time frame: 24 hours

Other outcomes

  1. Patients' approval

    We evaluate the grade of approval of patients with a questionnaire

    Time frame: At 24 hours

07

Study locations

1 site
  • Campus Bio-Medico
    Rome, 00128, Italy
08

References and documents

Publications

  • Lee AR, Yi HW, Chung IS, Ko JS, Ahn HJ, Gwak MS, Choi DH, Choi SJ. Magnesium added to bupivacaine prolongs the duration of analgesia after interscalene nerve block. Can J Anaesth. 2012 Jan;59(1):21-7. doi: 10.1007/s12630-011-9604-5. Epub 2011 Oct 20. PubMed 22012543 ↗
  • Ekmekci P, Bengisun ZK, Akan B, Kazbek BK, Ozkan KS, Suer AH. The effect of magnesium added to levobupivacaine for femoral nerve block on postoperative analgesia in patients undergoing ACL reconstruction. Knee Surg Sports Traumatol Arthrosc. 2013 May;21(5):1119-24. doi: 10.1007/s00167-012-2093-4. Epub 2012 Jun 14. PubMed 22696144 ↗
  • Dogru K, Yildirim D, Ulgey A, Aksu R, Bicer C, Boyaci A. Adding magnesium to levobupivacaine for axillary brachial plexus block in arteriovenous fistule surgery. Bratisl Lek Listy. 2012;113(10):607-9. doi: 10.4149/bll_2012_136. PubMed 23094900 ↗
  • Vastani N, Seifert B, Spahn DR, Maurer K. Sensitivities of rat primary sensory afferent nerves to magnesium: implications for differential nerve blocks. Eur J Anaesthesiol. 2013 Jan;30(1):21-8. doi: 10.1097/EJA.0b013e32835949ab. PubMed 23138572 ↗
  • Bailard NS, Ortiz J, Flores RA. Additives to local anesthetics for peripheral nerve blocks: Evidence, limitations, and recommendations. Am J Health Syst Pharm. 2014 Mar 1;71(5):373-85. doi: 10.2146/ajhp130336. PubMed 24534592 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in Jul 2020, 76 months.

Of 49 non-industry interventional studies with no phase under Hallux Valgus, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 55. This study's 76 months is above that.

Counting every sponsor, half of 54 studies reached it within 26 months; a quarter within 11 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2014
First posted
Jul 23, 2014
StartActual
Mar 2014
Primary completionActual
Jul 1, 2020
CompletionActual
Sep 1, 2022
Last update
Aug 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02198547
Lead sponsor
Campus Bio-Medico University
Responsible party
Massimiliano Carassiti (MD, Campus Bio-Medico University) — Principal investigator
First posted
Jul 23, 2014
Start date
Mar 2014
Primary completion
Jul 1, 2020
Completion
Sep 1, 2022
Last update
Aug 26, 2024

Study contacts

Massimiliano Carassiti, MD
principal investigator · Campus Bio Medico

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Magnesium Sulfate

Start the discussion